Repare Therapeutics was co-founded by researchers from Lunenfeld-Tanenbaum Research Institute, University of Toronto and New York University.

Imprimis Pharmaceuticals spinout Eton Pharmaceuticals has secured $20m in a private placement from a syndicate of unnamed investors.

Baxalta-backed Syntimmune has raised $50m in an Apple Tree Partners-led series B round that will fund clinical development of its autoimmune diseases treatment.

Sleep aid developer Rythm has disclosed $22m of funding from investors including insurance company Maif, about $11m of which it has secured since early 2016.

Gamida Cell has raised new funding from a consortium including Novartis, a shareholder since 2014 when it invested $35m in the cellular therapy developer.

Sanovas has signed an agreement with the government of Suzhou in China to create a $75m fund and innovation centre at the Chinese Academy of Sciences.

The eye disease treatment developer has raised $7.5m in a round co-led by pharmaceutical company Abdi Ibrahim, six months after closing a $6m series A.

OSF HealthCare's corporate venturing unit has led a series A round for mental health telemedicine provider Regroup Therapy.

Optum Ventures was among the contributors to a series A round that will fund the mental health diagnostics platform's R&D activities.

The technology is based on research at University of Maryland, Baltimore and University of Maryland, College Park.